Loading news...
Access Investment Management LLC reduced its stake in Integra LifeSciences Holdings Corporation (NASDAQ: IART) by 14.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 372,450 shares of the life sciences company's stock after selling 63,420 shares during the period.
Hussman Strategic Advisors Inc. purchased a new stake in shares of Integra LifeSciences Holdings Corporation (NASDAQ: IART) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 168,000 shares of the life sciences company's stock, valued at approximately $2,407,000. Hussman Strategic Advisors Inc. owned
FMS, IART and STE trade below historical valuations. Easing cost pressure and improved execution set the stage for potential upside in 2026 for these companies.
Integra LifeSciences Holdings Corporation (IART) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Shares of Integra LifeSciences Holdings Corporation (NASDAQ: IART - Get Free Report) have earned an average rating of "Reduce" from the seven research firms that are currently covering the company, MarketBeat reports. Three analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to
PRINCETON, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief executive officer Mojdeh Poul and chief financial officer Lea Knight will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 2:15 p.m ET or 11:15 a.m PT
Assenagon Asset Management S.A. lessened its stake in shares of Integra LifeSciences Holdings Corporation (NASDAQ: IART) by 62.0% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 454,352 shares of the life sciences company's stock after selling
Integra LifeSciences Holdings Corporation (IART) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
PRINCETON, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief executive officer Mojdeh Poul and chief financial officer Lea Knight will present at the Citi 2025 Global Healthcare Conference on December 3, 2025 at 10:30 a.m ET A live webcast of the presentation will be available on the Integra LifeSciences investor relations website under EVENTS & PRESENTATIONS.
PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, commends the Centers for Medicare & Medicaid Services (CMS) on its Calendar Year 2026 Medicare Physician Fee Schedule and Outpatient Prospective Payment System rules.
AXQ Capital LP bought a new position in shares of Integra LifeSciences Holdings Corporation (NASDAQ: IART) in the second quarter, according to the company in its most recent filing with the SEC. The fund bought 23,344 shares of the life sciences company's stock, valued at approximately $286,000. Several other hedge funds have also
PRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, is pleased to announce the FDA 510(k) clearance for use of its CUSA® Clarity Ultrasonic Surgical Aspirator System for cardiac surgeries.
Integra LifeSciences Holdings Corporation ( IART ) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Company Participants Christopher Ward - Senior Director of Investor Relations Mojdeh Poul - President, CEO & Director Lea Knight - Executive VP & CFO Conference Call Participants Vikramjeet Chopra - Wells Fargo Securities, LLC, Research Division Ryan Zimmerman - BTIG, LLC, Research Division Ravi Misra - Truist Securities, Inc., Research Division Lilia-Celine Lozada - JPMorgan Chase & Co, Research Division Presentation Operator Good day, and welcome to the Integra LifeSciences Third Quarter 2025 Financial Results. [Operator Instructions] As a reminder, this call may be recorded.
While the top- and bottom-line numbers for Integra (IART) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Integra LifeSciences (IART) came out with quarterly earnings of $0.54 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.41 per share a year ago.
PRINCETON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2025.
PRINCETON, N. J. , Oct. 15, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, will release third quarter 2025 financial results on Thursday, October 30, 2025, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.
Featuring Durepair® Dura Regeneration Matrix and Mayfield® Ghost™ Base Unit, Post Featuring Durepair® Dura Regeneration Matrix and Mayfield® Ghost™ Base Unit, Post
PRINCETON, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the appointment of Dr. Raymond Turner as its new corporate vice president and chief medical officer.
IART shows strong demand in neurosurgery and Tissue Technologies but faces macro and liquidity challenges.